The purpose of this study is to determine a safe and effective dose range for intravenous administration (infusion) of PDC31 by determining the maximum tolerated dose of PDC31 in patients with primary dysmenorrhea.

This is an open-label, multi-centre, dose-escalating first-in-human Phase I study of PDC31 in patients with primary dysmenorrhea aimed at determining the maximum tolerated dose (MTD) of PDC31 in this patient population.

Inclusion Criteria:

• Otherwise healthy females with a history of primary dysmenorrhea
• Using effective birth control excluding intrauterine contraceptive device (IUCD)
• Must be 18 years of age or older
• Must give written informed consent to participate in this study

Exclusion Criteria:

• Patients with an intrauterine contraceptive device or using oral contraceptives within 3 months of treatment in this study
• Patients with confirmed pelvic inflammatory disease, endometriosis or adenomyosis
• Patients who are pregnant or who test positive at baseline or are at risk of becoming pregnant while on study
• Patients who are breastfeeding
• Patients with hepatic or renal function tests greater than the upper limit of normal and deemed clinically significant by the Investigator at screening
• Patients with a clinically significant medical or psychiatric disorder or a serious medical conditions within the past 6 months which in the opinion of the investigator, should prohibit participation in this study
• Patients who have been exposure to any investigational drug within 4 weeks prior to screening